Blog

Company News

Industry Trends

Laws Regulations

All Categories >

20

2025-10

Exhibition Invitation | IGC2025: The 10th International Conference on Research, Development, and Industrialization of Cells and Derivatives

The 10th IGC 2025 Conference on Cell and Derivative R&D and Industrialization will be grandly inaugurated at the Langham Guangzhou on October 30–31. Leveraging the policy advantages of the Greater Bay Area, this year’s event features a plenary session and four specialized tracks, bringing together experts from more than 60 leading research institutions—including West China Lecity, Xiangxue, Baiji, Dabao, China Resources, Guanhao, Keyi, Beike, Sinovac, Laen, Tiankeya, Qianhui, Elp, Xidi, Ruizhen, Sipu, Ai Yi, and Aixiuma—as well as CEOs of industry-leading companies and partners from prominent investment firms, to jointly explore cutting-edge fields such as in vivo immune cell therapy, MSC/iPSC stem cell therapy, exosome-based therapies, and anti-aging medical aesthetics.

2025-10-20

He Yousheng

15

2025-09

Little “Sheng” Has a Reason Learning Hall | TDCC Experimental Skills Intensive Training Course

With the rapid advancement of cancer immunotherapy, novel therapeutic modalities such as bispecific antibodies, immune cell engagers, and adoptive cell therapies have emerged one after another. A core mechanism underlying these approaches is the redirection and activation of T cells to achieve specific cytotoxicity against tumor cells. The T cell–dependent cellular cytotoxicity (TDCC) assay, regarded as the “gold standard” for in vitro efficacy assessment of such agents, plays a pivotal role in drug screening, mechanistic studies, and preclinical evaluation.

2025-09-15

He Yousheng

21

2025-08

Good News! Hycells Supports Qihan Bio’s Universal CAR-T Therapy in Obtaining FDA Approval!

On August 13, 2025, Qihan Bio, a biotechnology company dedicated to applying high-throughput gene-editing technologies to cell therapy and organ transplantation, announced that its Investigational New Drug application for QT-019B, the company’s first independently developed universal, dual-target CAR-T cell product, has received formal approval from the U.S. FDA. QT-019B is the first universal CAR-T cell product for the treatment of autoimmune diseases that has been independently developed by a Chinese company and granted U.S. FDA clinical trial approval.

2025-08-21

He Yousheng

21

2025-08

Hycells Bio & InnoCell | Integrated Cell Subtype Sorting Solution

Peripheral blood mononuclear cells (PBMCs) are a population of cells in peripheral blood that possess a single nucleus, primarily comprising lymphocytes and monocytes. According to the Biosecurity Law of the People’s Republic of China, which came into effect on April 15, 2021, human-derived samples must be obtained in a lawful and compliant manner. The Innops Human Immune Cell Sorting Kit provides safe and reliable healthy human-derived samples for use as controls.

2025-08-21

He Yousheng

11

2025-08

Cell Feeder bottom-permeable cell culture flasks | High-yield protocol for immune cell expansion, no medium change or replenishment required after 7 days.

Cell culture flasks serve as vessels for cell culture and expansion, offering the advantage of accommodating large cell densities and supporting long-term cultivation. These flasks typically feature a high surface-area-to-volume ratio, which promotes adherent cell growth and efficient nutrient exchange, facilitates subculturing and expansion, and meets the demands of research requiring large cell numbers. However, when using conventional cell culture flasks for cell expansion, frequent manual interventions are necessary to adjust cell density and replenish fresh culture medium, thereby increasing the risk of contamination. In contrast, permeable culture bags or bioreactors represent alternative approaches for large-scale production of CIK, T, and NK cells. Yet, culture bags require substantial volumes of fresh medium and frequent adjustments of cell density, while visual monitoring is inconvenient and relies on sampling or external sensors to assess cell status; bioreactors, on the other hand, are bulky, expensive, and complex to operate. The G-Rex series of culture flasks has been widely validated and adopted by users; however, this series is costly and subject to supply instability.

2025-08-11

He Yousheng

07

2025-07

When we stand together, we achieve the extraordinary—A complete record of Hycells Bio’s 2025 mid-year team-building event!

The June sun shines warmly and brightly, prompting the team at Heyou Bio to momentarily set aside their pipettes and culture flasks. Leaving behind the cell culture rooms and laminar flow hoods, they head off to fulfill a promise—a bond between the team and nature. While experimental data demands rigor, team-building activities call for even more excitement!

2025-07-07

He Yousheng
< 1...345...20 >